ReportGemReportGem 中文

PUBLIC COMPANY RESEARCH HUB

Merck & Co., Inc. (MRK) Filings, Earnings Calls and Research

A source-backed research workspace for Merck & Co., Inc.. Compare recent disclosures, management commentary and foreign research coverage without losing the original evidence trail.

Evidence documents4
Filings3
Meetings0
Research1
Displayed research share25%
Latest evidence2026-08-19

Foreign research

Quick Take: MRNA/MRK‘s INT successful at first IA for Melanoma ph3 (we expect data at ESMO)2026-08-19 · Bernstein

Primary-source evidence

10-K FOR THE FISCAL YEAR ENDED DECEMBER 31, 20252026-02-24 · SEC EDGAR · 10-K

Merck reported 2025 worldwide sales of $65.0 billion, up 1% YoY, with GAAP EPS of $7.28 and non-GAAP EPS of $8.98. R&D expenses declined 12% to $15.8 billion. Key business development activities included the acquisition of Cidara Therapeutics for ~$9.2 billion…

3Q25 FORM 10-Q2025-11-05 · SEC EDGAR · 10-Q

Merck's Q3 2025 sales rose 4% to $17.28B, with nine-month sales of $48.61B. Net income increased 14% to $15.30B. R&D expenses declined due to prior-year acquisition charges. Issued $6B notes to fund Verona Pharma acquisition.…

FORM 8-K2025-10-30 · SEC EDGAR · 8-K

Merck & Co., Inc. filed a Form 8-K on October 30, 2025, reporting third-quarter 2025 earnings. The filing incorporates by reference a press release (Exhibit 99.1) and supplemental information (Exhibit 99.2), but no specific financial figures are provided in th…

Questions this evidence can help answer

  • What changed in the latest research coverage of Merck & Co., Inc.?
  • Which operating and valuation themes recur across institutions?
  • Which claims should be checked against company primary-source evidence?
Research this company with AI